By
updated 11/11/2010 1:00:35 PM ET 2010-11-11T18:00:35

Federal health regulators have approved the first drug to eliminate excess fat that develops as a side effect of HIV treatments.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The Food and Drug Administration announced Wednesday it approved Egrifta for lipodystrophy, which causes excess fat in the liver, stomach and other abdominal organs. The condition is common in patients taking anti-viral drugs used for HIV.

Egrifta is injected once daily.

Pharmaceutical developer Theratechnologies Inc. studied its drug in more than 800 HIV patients with abdominal fat. After six months of treatment, patients taking Egrifta had significantly less fat than patients who received a placebo injection. The most common side effects reported with the drug included joint pain, skin redness and rash.

The FDA stressed in a press release that the drug has not been proven to decrease the risk of heart disease or other complications.

Egrifta was developed by Montreal-based Theratechnologies and marketed in the U.S. by Rockland, Mass.-based EMD Serono.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments